The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
This MoU will further strengthen relations between India and the USA within the framework of international scientific and technological cooperation in fields of mutual interest.
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
This cost-effective tool will be of immense benefit to other high burden countries as well.
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
The EBUS is designed to support the diagnosis and staging of various lung disorders
Subscribe To Our Newsletter & Stay Updated
